Skip to main content
Premium Trial:

Request an Annual Quote

MDS Sciex Says Q4 Organic Revenues Inched Up 1 Percent

NEW YORK (GenomeWeb News) — MDS today reported that fourth-quarter revenue for its Sciex division declined 5.5 percent to $69 million from $73 million year over year.
 
The company blamed the decline on currency effects but said organic revenues were up 1 percent.
 
MDS said Sciex’s organic increases came from growth in the small-molecule business and high-end triple quad and trap products, and from growth in India and China.
 
MDS did not break down R&D spending for the Sciex division but said that spending was down year over year because two products, the CellKey System and 4800 platforms have entered commercial production.
 
The company also did not break out earnings or a balance sheet for the unit.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.